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ABSTRACT
Neuroblastoma is one of the most common solid neoplasms in children, which
affects sympathetic neurons with a wide range of genetic abnormalities, especially
MYCN amplification, a molecular marker of poor prognosis. Despite advance therapy,
still the mortality rate for advance disease is high with frequent relapse and resistance to
cytotoxic therapy with evidence of p53 mutation. Metformin, an oral hypoglycemic
medication, is a relatively safe and cost effective drug with wide clinical applications,
mainly for treatment of Type 2 diabetes. Recent studies have showed promising
anticancer effect of metformin on various cancer types, especially on p53 mutant cells. In
our research, we performed in vitro study testing the effect of metformin on
neuroblastoma cells, as little is known about its effect on this disease. Our results
demonstrate that metformin at 10 and 20 mM has significant growth and survival
inhibitory effects on both N-myc amplified and N-myc non-amplified and p53 mutant
cells. Metformin induces apoptosis in both cell types revealed by morphological changes
and detection of cleaved caspase3 by western blot analysis. Metformin’s anticancer effect
may be independent on AMPK and AKT pathways as our initial results show no marked
change relative to control. Metformin decreases total RhoA protein expression in both
cell lines and total Rac1 protein expression in N-myc amplified cells. Our results suggest
that metformin can be a good and safe candidate for treatment of neuroblastoma.
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CHAPTER 1
INTRODUCTION
1.1 Neuroblastoma:
Neuroblastoma is the third most prevalent childhood malignancy, after acute
lymphocytic leukemia (ALL) and CNS and brain tumors, and it is the commonest
neoplasm encountered in children below one year of age (American Cancer Society,
2014;Chakrabarti, Abou-Antoun, Vukmanovic, & Sandler, 2012). Neuroblastoma
represents 7% of all childhood malignancy and up to 15% of cancer related mortality
(American Cancer Society, 2014; Davidoff, 2012). In the United States, around 700 new
cases of neuroblastoma are diagnosed each year with approximate incidence of 10.2 cases
per1,000,000 children below 15 years old (Davidoff, 2012; Cheung & Dyer, 2013).
Neuroblastoma is a heterogeneous embryonic tumor affecting postganglionic
sympathetic neurons with wide variety of clinical presentations and genetic aberrations
(Normand, Michon, Janoueix-Lerosey, Delattre, & Schleiermacher, 2011). It generally
tends to affect males slightly more than females and white children more than other races
(American Cancer Society, 2014) . Neuroblastoma disease could in some cases regress
spontaneously or it can undergo differentiation into more benign form ganglioneuromas
(Weinstein, Katzenstein, & Cohn, 2003) . However, up to half of cases are associated
with metastatic presentations at time of diagnosis with overall survival rate around 40%
1

(Matthay, Weiss, et al., 2012). Most cases of neuroblastoma are sporadic with various
genetic abnormalities, and no definitive environmental factors have been found
predisposing to its development (Weinstein et al., 2003). On the other hand, only 1- 2%
of neuroblastoma are familial cases with early onset of the disease and with multiple
primary tumor foci detected at time of diagnosis (Maris et al., 2002).
Despite the increase in the survival rates of neuroblastoma in general (around
79% survival rate during 2003-2009 compared to the 54% in the previous years), the
survival rate of high risk neuroblastoma patients remains low, with increased morbidity
due to complications of intensified chemotherapeutic treatment (American Cancer
Society, 2014).
1.1.1 Pathogenesis and genetic abnormalities:
Neuroblastoma is a malignant tumor involving sympathetic neurons, mainly
adrenal medulla and paraspinal sympathetic nerves (Normand et al., 2011).
Neuroblastoma originates from sympathoadrenal precursor cells which are derived from
neural crest cells (Cheung & Dyer, 2013). Neural crest cells are group of embryonic cells
which are found in neural plate border region of developing embryo (Dupin & Sommer,
2012). These neural crest cells can give rise to different cell types, such as: melanocytes
of epidermis, smooth muscle cells of vessels, craniofacial bone, glia and Schwann cells,
enteric and peripheral neurons, olfactory cells, adipocytes, meninges and adrenal medulla
(Cheung & Dyer, 2013; Dupin & Sommer, 2012). During embryonic development, some
of neural crest cells migrate from their original site to the dorsal aorta where they become
sympathoadrenal lineage cells (Cheung & Dyer, 2013). In turn, sympathoadrenal
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precursor cells further differentiate, in response to many signals, into paraspinal
sympathetic ganglia or chromaffin cells comprising adrenal medulla(Cheung & Dyer,
2013).

Figure 1.1 “Development of the lineages derived from neural crest cells and the origin of
the different stages of neuroblastoma (NB)”. Reused from “Neuroblastoma therapy: what
is in the pipeline?” by Verissimo, C. S., Molenaar, J. J., Fitzsimons, C. P.,& Vreugdenhil,
E. (2011). Endocr Relat Cancer, 18(6), R213-231, figure 1. doi: 10.1530/ERC-11-0251
Copyright © [2011] [BioScientifica Ltd]. Reused with permission.
Several signaling pathways and genes are well regulated during embryogenesis
and contribute to accurate differentiation of these precursor cells to become specialized
neuronal cells, such as: paired-like homeobox2b (PHOX2B), which is important for
neuronal cells differentiation, and anaplastic lymphoma receptor tyrosine kinase (ALK)
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gene, which control MAPK and RAS-related protein 1 (RAP1) signaling pathways in
order to regulate neuronal cell proliferation and differentiation (Cheung & Dyer, 2013;
Verissimo, Molenaar, Fitzsimons, & Vreugdenhil, 2011). Similarly, MYCN protooncogene, located on chromosome 2p24, is found to be involved in neuronal precursor
cells proliferation and inhibition of their differentiation during embryogenesis(Davidoff,
2012; Verissimo et al., 2011).
Although the exact genetic causes of neuroblastoma are not well understood,
disruption or overexpression of these signaling factors are linked to the development of
neuroblastoma, besides other genetic aberrations (Santo et al., 2013).In familial
neuroblastoma, two common mutations can be found: mutation in paired-like
homeobox2b (PHOX2B) gene, or more commonly ALK gene mutation in germ line
which is also found as a somatic cell mutation or amplification in approximately 8% of
sporadic neuroblastoma cases (Cheung & Dyer, 2013; Van Roy et al., 2009). Besides,
several genetic abnormalities are encountered in most neuroblastoma cases, especially in
advance stages, including: DNA ploidy, chromosomal loss, mutations of specific genes,
and most importantly MYCN amplification (Davidoff, 2012). N-myc proto-oncogene, a
transcription factor belongs to the basic-helix-loop-helix-zipper (bHLHZ) class, is
amplified in about 22% of neuroblastoma cases, predominately in metastatic disease, and
associated with poor prognosis (Knoepfler, Cheng, & Eisenman, 2002; Cheung & Dyer,
2013). MYCN amplification in neuroblastoma can be found in two different forms: extrachromosomal fragments as double-minute chromatin bodies (DMs), or homogeneously
staining regions (HSRs) within the chromosome (Davidoff, 2012). N-myc, which is
commonly amplified in advance neuroblastoma, can heterodimerize with MAX protein in
4

DNA specific sequences and promote transcription (Knoepfler et al., 2002). However, the
exact contribution of MYCN amplification to the development of

aggressive

neuroblastoma, which is associated with poor outcome , remains unknown (Van Roy et
al., 2009). Other genetic abnormalities commonly detected in neuroblastoma include:
change in the number of chromosomes or individual chromosomal abnormalities, which
associate with various outcomes(Normand et al., 2011). DNA ploidy generally refers to
the DNA content within the cell (2 copies of each 23 chromosomes are normally found in
diploid cells) (Davidoff, 2012). In primary neuroblastoma disease, up to 55% of cases
contain near triploid or triploid cells, while the rest 45% cases harbor near-diploid or
near-tetraploid cells(Davidoff, 2012). Similarly, chromosomal abnormalities frequently
encountered in neuroblastoma are: gain of chromosome 17q and loss of chromosomal
regions 1p,11q, and 3p (Normand et al., 2011). Chromosome 17q gain are found in up to
80% of cases due to unequal translocation with other chromosomes (chromosome 1p or
chromosome 11q) in tumor cells (Van Roy et al., 2009). Another common chromosomal
abnormality is loss of chromosome1p in up to 25-35% of cases, which may contain
cancer suppressor genes (Van Roy et al., 2009). Deletion of chromosome 1p is frequently
detected in neuroblastoma cases, particularly in advanced disease when it commonly
correlate with MYCN amplification (Davidoff, 2012; Van Roy et al., 2009). Moreover,
several other chromosomal loss, which might contain cancer suppressor genes, are
frequently found in neuroblastoma tumor without association with MYCN amplification,
these include: chromosome 11q loss commonly found in high stage neuroblastoma, and
chromosome 3p loss in association with loss of chromosome 11q commonly found in
older patients (Van Roy et al., 2009).
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Genetic mutations in neuroblastoma is not only confined to the primary tumor but
also can be found after cytotoxic therapy in relapsed neuroblastoma (Carr-Wilkinson et
al., 2010; Tweddle, Malcolm, Bown, Pearson, & Lunec, 2001). Mutations in p53, a tumor
suppressor gene located on short arm of chromosom17, are rare in primary
neuroblastoma at time of diagnosis (Tweddle et al., 2001). However, several studies have
shown that p53 mutations could be found in relapsed neuroblastoma after chemotherapy
(Tweddle et al., 2001; Carr-Wilkinson et al., 2010). P53 is a transcription factor that
binds specific DNA sequence and promotes transcription of p21, MDM2 and BAX genes
in response to DNA damage, which in turn involve in regulation of cell cycle and
apoptosis (Tweddle et al., 2001; Carr-Wilkinson et al., 2010). In neuroblastoma cells
from relapsed cases, it was found that p53 is frequently inactivated by genetic mutation
or the p53/MDM2/p14ARF pathway that control p53 in the cell is mutated.(Tweddle et al.,
2001; Carr-Wilkinson et al., 2010). These genetic abnormalities are used clinically as
prognostic markers, especially MYCN amplification, in diagnosis, staging, and prediction
of prognostic outcome of the patient (Lonergan, Schwab, Suarez, & Carlson, 2002). In
addition they are used to determine the appropriate strategy for treatment, which range
from observation and surgery alone for low risk patients to the use of more intensified
cytotoxic therapy for high risk disease (Davidoff, 2012).

1.1.2 Clinical presentations of neuroblastoma:
Neuroblastoma is the most frequently encountered extracranial solid malignancy
in children, and it is mainly diagnosed during infancy and in children below 5 years
(around 90%) (Van Roy et al., 2009; Verissimo et al., 2011). The median age of
diagnosis is around 18 months for sporadic cases, while in familial neuroblastoma it is
6

around 9 months with frequent presentation of bilateral or multifocal malignancy
(Brodeur, 2003). Neuroblastoma can develop in different places along the sympathetic
neurons but the majority arises in the lumber sympathetic neurons and adrenal medulla
(around 65%), whereas the rest cases can occur anywhere through the sympathetic
neurons in chest, neck, or pelvic regions in a ratio of 4/1/1, respectively (Cheung & Dyer,
2013).
The clinical presentations of neuroblastoma vary depending on the effect of
primary tumor and distant metastasis(Maris, 2010; Papaioannou & McHugh, 2005;
Papaioannou & McHugh, 2005). The primary tumor usually presents as palpable mass in
the abdomen, especially in case of adrenal involvement, or mass in the neck or chest due
to involvement of corresponding sympathetic neurons (Maris, 2010). In addition,
neuroblastoma growth may involve vital structures or press the surrounding tissues, blood
vessels, and nerves, especially in high stage disease, which can lead to various signs and
symptoms, including: blood vessels involvement such as renal arteries, Horner’s
syndrome due to involvement of cervical neurons, and pressure effect of growing tumor
on spinal cord which leads to various neurological defects (Papaioannou & McHugh,
2005).
In neuroblastoma cases with metastasis, infiltration of surrounding tissues can
lead to various presentations, such as: liver enlargement especially in stage 4S disease,
blindness due to involvement of optic nerve, lymph node enlargement, and infiltration of
bone marrow with fever, malaise, anemia and bone pain.(Papaioannou & McHugh,
2005).
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1.1.3 Diagnosis, Staging and risk group classification:
Diagnosis of neuroblastoma is based mainly on histopathological examination, bone
marrow aspiration, laboratory tests and radiological investigations which also help in
disease staging and predicting patient outcome (Weinstein et al., 2003). Ultrasonography
is the initial technique commonly used to detect abdominal neuroblastoma mass and
determine its location, similarly, plain radiograph is helpful in the detection of primary
tumor and metastasis (Papaioannou & McHugh, 2005). However, CT scan and MRI are
the main techniques used for definitive diagnosis and staging of the disease, beside,
Scintigraphy ,using

99

mTc-MDP and

123

I-MIBG, is commonly used for diagnosis of

primary tumor and searching for metastatic lesions (Papaioannou & McHugh, 2005;
Weinstein et al., 2003). Laboratory tests frequently used in diagnosis of neuroblastoma
include: histochemical testing of bone marrow sample and urinary testing of
catecholamine level(Papaioannou & McHugh, 2005). Histological examination of
neuroblastoma generally reveals presence of undifferentiated small round neuronal cells
(Neuroblastoma cells), and in some cases tumor cells exhibits mild degree of histological
differentiation (ganglioneuroblastomas) (Brodeur, 2003). On the other hand, in the more
mature form of the disease the histological examination shows mature neuronal cells
within Schwann rich stroma (Brodeur, 2003).
Generally, neuroblastoma is classified into favorable and unfavorable
histopathological prognostic groups based on Shimada histopathological classification in
1984(Weinstein et al., 2003). This classification takes into account age of the patient at
time of diagnosis (<1.5 years,1.5–5 years, or >5 years) and histologic criteria including:
presence of schwannian stroma whether rich (mature) or poor (immature), degree of
8

cellular differentiation (undifferentiated, differentiated or mixed), and the mitosis and
karyorrhexis index (MKI) (low, intermediate and high) (Lonergan et al., 2002; Weinstein
et al., 2003). MKI represents the summation of tumor cells with mitosis and karyorrhexis
per 5,000 cells sample (Lonergan et al., 2002). According to this classification, patients
with favorable histopathology are those who are < 1.5 years old with at least partially
differentiated tumor and low or intermediate MKI or those who are 1.5–5 years old with
differentiated tumor and a low MKI , however, the remaining groupings are classified as
unfavorable histopathology (Lonergan et al., 2002).
Furthermore, neuroblastoma is commonly classified into different stages based on
clinical, surgical and radiologic criteria of the International Neuroblastoma Staging
System (INSS), established in 1988 and modified in 1993(Lonergan et al., 2002;
Weinstein et al., 2003). In this staging system, the classification of neuroblastoma
generally ranges from stage1 disease, in which tumor is localized and carry good
prognosis, to stage 4 disease, in which tumor is metastasized and carry poor
prognosis.(Lonergan et al., 2002; Weinstein et al., 2003). In addition, there is another
stage called stage 4S (stage 4 “special”) represents 7-10% of neuroblastoma cases and
includes the following criteria: presence of small primary tumor, age <12 months, and
evidence of distance metastasis confined to the liver, skin and <10% of bone marrow,
which generally carries good prognosis with disease free survival rate up to 57–87%
(Schleiermacher et al., 2003).
In 2009, International Neuroblastoma risk group staging system (INRGSS)
classifies neuroblastoma into 4 stages (L1, L2, M, and MS) using radiographic
investigation, and this classification is based mainly on extent, stage, and risk factors of
9

the tumor (Cohn et al., 2009; Van Roy et al., 2009). L1 and L2 denote local disease, M
for metastatic tumor, and MS for tumor encountered in children below18 months with
similar stage 4S metastatic criteria (Cohn et al., 2009; Van Roy et al., 2009). Based on
this staging system and molecular prognostic factors, neuroblastoma is further classified
according

to

International

Neuroblastoma

Risk

Group

(INRG)

Pretreatment

Classification into 4 main categories (very low, low, Intermediate, and high risk) with 16
pretreatment groups (A-R), to determine overall prognosis and suitable treatment for
patients (Cohn et al., 2009). According to this classification, the overall 5 years event free
survival (EFS) for patients with very low risk group (A, B, C) about 85%, low risk
group(D, E, F)75%-85%, intermediate risk group (G, H, I, J) 50% -75%, and high risk
group (K, N, O, P, Q, R) below 50% (Cohn et al., 2009).

1.1.4 Treatment of neuroblastoma:
Current treatment of neuroblastoma is based on children’s oncology group (COG)
neuroblastoma risk classification, in which patients are categorized into 3 major groups:
low risk group, intermediate risk group, and high risk group (Davidoff, 2012). This risk
group classification is based on various prognostic criteria, including: stage of the tumor,
age of the patient at time of diagnosis, presence of MYCN amplification, DNA ploidy
status, histological features (favorable or unfavorable histology), and others including the
percent of tumor which is resected (Henderson et al., 2011). Patients with low risk
neuroblastoma are those with stage1, stage 2A/2B with > 50% of tumor resected, or stage
4S diseases with favorable histology and DNA Index(DI) >1, and all these stages without
evidence of MYCN-amplification (Davidoff, 2012; Henderson et al., 2011). Intermediate
risk group includes patients up to one year old with stage 2A/2B disease and the tumor
10

undergo biopsy only or <50% resected, patients up to1.5 years with stage 3 tumor, those
between 1.5-12 years old with stage 3 disease and favorable histology, patients 1-1.5
years with stage 4 disease and favorable histology with DI >1, or symptomatic patients
with stage 4S and unfavorable histology or DI equal to 1, and all these stages without
MYCN amplification(Davidoff, 2012; Henderson et al., 2011). High risk group are those
with stage 4 disease and > 1.5 years old, patients with stage(2A/2B,3,4, or 4S) with
evidence of MYCN amplification, patient with stage 3 with unfavorable histology and
>1.5 years old, or patients between 1-1.5 years old with advance stage 4 disease that has
either unfavorable histology or DI=1 (Davidoff, 2012; Henderson et al., 2011).
Accordingly, low risk group patients are generally treated with surgery alone, or
sometimes observation and biopsy, especially for infant with favorable stage 4S disease
(Davidoff, 2012). Intermediate-risk groups are treated with chemotherapy and surgical
removal of resectable tumor, while those with high-risk illness generally require intensive
chemotherapy (myeloablative therapy), stem cells transplantation, radiotherapy and
reducing tumor mass surgically (Davidoff, 2012).
However, more than 50% of high risk cases relapse and develop resistance to
chemotherapy after initial response (Carr-Wilkinson et al., 2010). In recent years, more
efforts have been made to develop targeted therapy in order to improve the treatment of
neuroblastoma, which ultimately may lead to increase overall survival of the patients
(Matthay, George, & Yu, 2012). One of these approaches depends on using small
molecules to inhibit ALK, a tyrosine kinase commonly mutated in familial neuroblastoma
and in up to 6-10% of sporadic cases (Cheung & Dyer, 2013; Matthay, George, et al.,
2012). The second approach is by immune destruction of cancer cells using antibodies
11

specific for GD2 a (Disialoganglioside), a specific cell surface antigen presenting in
around 98% of neuroblastoma cases(Davidoff, 2012);(Cheung & Dyer, 2013; Matthay,
George, et al., 2012). Another recent approach is to use

131

I-metaiodobenzylguandine

(MIBG) (norepinephrine analogue) commonly used for staging of neuroblastoma disease
(Matthay, Weiss, et al., 2012). This therapy targets norepinephrine transporter expressed
in around 90% of neuroblastoma cancer cells, then these cancer cells are destroyed using
radiotherapy(Matthay, George, et al., 2012; Matthay, Weiss, et al., 2012). These targeting
therapies for the treatment of neuroblastoma disease are being used in early clinical trials
with promising results, however, each one of these therapy may cause considerable side
effects, such as

the risk of radiation accompany MIBG therapy and cell toxicity

accompany anti GD2 immunotherapy, which require further evaluation of these new
approaches to minimize their adverse effects (Matthay, George, et al., 2012).

1.2 Metformin:
Metformin (N’,N’-dimethylbiguanide) is the most commonly used oral
hypoglycemic medication in the treatment of non-insulin dependent (type2) diabetes
mellitus worldwide (Ben Sahra, Le Marchand-Brustel, Tanti, & Bost, 2010; Gong,
Goswami, Giacomini, Altman, & Klein, 2012). Metformin belongs to biguanide family,
which also includes two other compounds phenformin and buformin (Dowling, Goodwin,
& Stambolic, 2011). Metformin is originally derived from the French Lilac herb (Galega
officinalis) and was used as a herbal tea during the medieval Europe and ancient Egypt to
treat symptoms similar to type 2 diabetes, including polyuria and halitosis (Dowling et
al., 2011). Biguanide contains guanidine active component that was first discovered in
1900s to have antidiabetic proprieties, which eventually lead to the synthesis of
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metformin and phenformin to be used clinically as antidiabetic drugs(Quinn, Kitagawa,
Memmott, Gills, & Dennis, 2013). Phenformin was used in the USA from 1957-1970s
when it was discontinued due to its side effect of sever lactic acidosis (Quinn et al.,
2013). On the other hand, metformin has been used to treat diabetic patients in Britain
since 1958 and in Canada since 1972, while it was first approved in the united states in
1995, due to its effectiveness and safety with the fact that the risk of lactic acidosis
associated with metformin treatment is very low (less than 1 per 10,000), mainly in
patients with impaired renal function (Ben Sahra et al., 2010; Dowling et al., 2011).
Besides, more than 120 million prescriptions per year of metformin are used worldwide,
and up to 40 million prescriptions of metformin were recorded in 2008 in the United
States alone, due to its important role in treating diabetes and improving the survival of
diabetic patients (Dowling et al., 2011; Kourelis & Siegel, 2012).

1.2.1 Pharmacological proprieties of metformin:
Metformin is given usually as an oral tablet,(Metformin HCL with MW 165.63),in
a dose ranging between 1500-2250 mg/day for adult, with an average plasma half-life
about 5 hours after administration (Graham et al., 2011; Dowling et al., 2011; Gong et al.,
2012). Metformin is positively charged molecule with hydrophilic properties, so it
requires transporters to enter cell membrane (Graham et al., 2011). After administration,
it is absorbed by gut plasma membrane and this may be through plasma membrane
monoamine transporters( PMAT), which are found mainly on luminal side of enterocytes,
or may be through OCT1 or OCT3 Organic Cation Transporters (Gong et al., 2012). Peak
plasma level of metformin in diabetic patients after one dose is about 0.5-2µg/ml or
around 4-15 µM, and then metformin is distributed and accumulated in different parts of
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body tissues, including: kidneys, salivary gland, duodenum, stomach, and liver (Quinn et
al., 2013). Metformin is distributed to the liver mainly through OCT1 transporters which
are found on the basolateral side of plasma membranes of hepatocytes, and may be
through OCT3 transporters which are also localized on basolateral side of these cells
(Gong et al., 2012). Metformin is distributed to other body tissues including heart,
muscle, and adrenal glands which express OCT1 and/or OCT3 transporters (Graham et
al., 2011). In addition, metformin uptake by the kidney is mainly through OCT2
transporters presented on basolateral side of plasma membrane of renal tubular cells, and
is excreted from the kidney via MATE1 and MATE2-K located on the apical membrane
of the renal proximal tubules, when metformin is then eliminated in the urine as
unchanged drug (Graham et al., 2011; Gong et al., 2012).

1.2.2 Metformin’s role in diabetic and non-diabetic insulin resistance
diseases:
Metformin is commonly used to treat type2 diabetes, which is characterized by
insulin resistance in peripheral tissue and associated hyperglycemia, without causing
considerable hypoglycemia or weight gain compared to sulfonylurea (Graham et al.,
2011; Pollak, 2012). Metformin exerts its antidiabetic action through reduction in hepatic
gluconeogenesis, increasing in peripheral tissue sensitivity to insulin, and increasing in
tissues use of glucose, particularly in muscle and adipose tissues (Gong et al., 2012; Ben
Sahra et al., 2010).
In the liver, metformin reduces gluconeogenesis by targeting mitochondrial
oxidative phosphorylation mainly through affecting respiratory chain complex 1, or
possibly by other indirect mechanisms (Dowling et al., 2011; Pollak, 2012). Ultimately
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metformin treatment leads to decrease in ATP production and increase in AMP and ADP
level (Quinn et al., 2013). The elevated AMP/ATP or ADP/ATP ratio leads to activation
of AMP-activated protein kinase AMPK, which can sense low energy condition (Quinn
et al., 2013). AMPK is a heterotrimeric serine/threonine protein kinase that has three
distinct catalytic and regulatory subunits including: α-subunit (with 2 isoforms), β
subunits (with 2 isoforms) and γ subunit (with 3 isoforms) (Quinn et al., 2013; Towler &
Hardie, 2007). AMP nucleotides activate AMPK by both allosteric binding to the enzyme
and by making it a good substrate to be phosphorylated by Liver Kinase 1 (LKB1), which
is the AMPK upstream kinase (Towler & Hardie, 2007). The activated (phosphorylated)
AMPK in turns affects different downstream targets to reduce mainly gluconeogenesis
and fatty acid and protein synthesis (Dowling et al., 2011). Activated AMPK leads to
inhibition of major gluconeogenesis genes and glucose production, inhibition SREBP-1
gene expression (lipogenic transcription factor) and decrease lipid synthesis, and
inhibition ACC (acetyl-CoA carboxylase enzyme) and fatty acid synthesis (Quinn et al.,
2013). However, recent study suggests that metformin can directly inhibit glucagon/PKA
signaling pathway that leads to inhibition of gluconeogenesis independent on AMPK
activation (Quinn et al., 2013).
In addition to its role in diabetes, metformin in many studies help in reducing
overall hyperinsulinemia and insulin resistance commonly found in patients with nondiabetics insulin resistance diseases, including : the use of metformin in the management
of polycystic ovarian diseases (PCOS), which is characterized by anovulation, excess
androgen and polycystic ovaries, and in the clinical trial for non- alcoholic fatty liver
diseases (NAFLD), which is characterized by fatty liver changes accompanied metabolic
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syndrome in absence of high alcohol consumption (Lashen, 2010; Mazza et al., 2012).
Moreover, recent clinical trial regarding the use of metformin in obese children with
insulin resistance demonstrated that metformin treatment associated with moderate effect
on body weight and composition in these children (Yanovski et al., 2011).

1.2.3 Metformin’s role in cancer:
In recent years, several epidemiological studies have linked metformin treatment
to lower incidences of cancer and cancer related mortality among diabetic patients (Ben
Sahra et al., 2010). Besides, these studies compare incidence of cancer risk among those
who are on metformin treatment with those who are on other antidiabetic medication
(Ben Sahra et al., 2010). In 2005, Evan et al published a pilot case-control study
regarding metformin treatment and cancer risk in patients with type 2 diabetes who
resided in Scotland, Tayside during 1993-2001 years, and the results suggested that
metformin treatment was correlated with low cancer risk among those patients (Viollet et
al., 2012; Evans, Donnelly, Emslie-Smith, Alessi, & Morris, 2005). These results are
followed by several epidemiological studies to test the role of metformin as anticancer
medication, for instance, in 2006, a published population-based cohort study found that
patients with type2 diabetes on sulfonylurea or insulin therapy have higher risk of cancer
death rate compared to those using metformin (Bowker, Majumdar, Veugelers, &
Johnson, 2006). Moreover, In 2012, Noto et al published a systemic review and metaanalysis of several published articles regarding metformin and cancer risk, and they
found that metformin was markedly associated with reduced incidence of cancer among
diabetic patients (Noto, Goto, Tsujimoto, & Noda, 2012). Similarly, In 2013, another
detailed systemic review was published including wide range of studies, conducted
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during 1966-2012, regarding the use of metformin and other hypoglycemic agents among
diabetic patients and their correlation with cancer risk (Franciosi et al., 2013). This
review showed that metformin might have a correlation with lower incidence of different
cancer types and associated cancer death (Franciosi et al., 2013).
In addition, several in vitro, in vivo, and clinical studies have been conducted in
recent years, exploring the role of metformin as anti-cancer agent for different cancer
types, and investigating the underlying molecular mechanisms (Pollak, 2012). In vitro
studies using metformin, with dose typically ranging between 5-30 mM, demonstrated
that metformin was able to inhibit cell growth in different cancer cell types such as lung,
colon, and pancreatic cancers (Ben Sahra et al., 2010). Besides, some in vitro studies
showed that metformin can induce apoptosis in different cell lines including triple
negative breast cancer and pancreatic cancer (B. Liu et al., 2009; Kourelis & Siegel,
2012; Ben Sahra et al., 2010).
Likewise, in vivo results using different cancer animal models demonstrated that
metformin treatment was able to reduce tumor growth significantly in wide range of
cancers, for instance, lung, colon, prostate, and triple negative breast cancer (Ben Sahra et
al., 2010; Kourelis & Siegel, 2012). Moreover, metformin at very low concentrations
specifically reduced growth of CD133+ pancreatic cancer stem cells (Gou et al., 2013). In
addition, metformin treatment was selectively able to impair cell growth in p53 mutant
colonic cancer (colon cancer) established in xenograft mice than p53 non mutant. (Buzzai
et al., 2007).
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The overall in vitro and in vivo studies suggest that metformin inhibits cell growth
and/or induces apoptosis through two possible ways: indirect (insulin dependent) and
direct (insulin independent) mechanisms (Dowling et al., 2011). Indirect mechanism
depends on the systemic effect of metformin in lowering insulin level through reduction
of hepatic glucose output and increasing tissue sensitivity to insulin (Dowling et al.,
2011; Kourelis & Siegel, 2012).

Figure 1.2 “Direct and indirect effects of metformin on cancer” reused from
“Understanding the benefit of metformin use in cancer treatment” by Dowling, R. J.,
Goodwin, P. J., & Stambolic, V. (2011). BMC Med, 9:33, figure 1. doi: 10.1186/17417015-9-33. © 2011 Dowling et al; licensee BioMed Central Ltd.
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In many cancer types, Insulin level is found to be elevated and the related receptor
tyrosine kinase signaling pathway is upregulated (Quinn et al., 2013). Insulin causes
activation of these receptors which send growth and survival signals to the cells through
PI3/AKT pathway (Dowling et al., 2011). So, metformin may reduce tumor growth
indirectly by reducing insulin dependent growth promoting signals to the cell (Dowling et
al., 2011).On the other hand, the direct mechanism is independent on insulin and
metformin may target different cancer cell pathways, including: AMPK-dependent
pathway and AMPK-independent pathway (Dowling et al., 2011; Quinn et al., 2013). In
AMPK dependent mechanism, metformin can work through affecting AMPK/mTORc1
pathway to inhibit protein synthesis and arrest cell growth(Quinn et al., 2013). In this
mechanism, metformin activates AMPK which in turn inhibits mTOR (the mammalian
target of rapamycin ), a major regulator of cell growth and metabolism (Dowling et al.,
2011; Quinn et al., 2013). Activation of AMPK can inhibit mTOR by two main
mechanisms: it can cause phosphorylation of tuberous sclerosis complex2 (TSC2) which
leads to buildup of Rheb-GDP (inactive form) and ultimately mTOR inhibition, or it can
phosphorylate raptor ( a regulatory molecule bound to mTOR and a substrate for AMPK)
which subsequently lead to inhibition of mTORc1(Quinn et al., 2013). mTORc1 controls
several downstream targets to regulate protein synthesis, transcription process, and
autophagy in the cell (Duran & Hall, 2012). mTORc1 activation leads to activation of
S6K (ribosomal protein S6 kinase) and inhibition of 4E-BP1(eukaryotic initiation factor
4E-binding protein-1), the two main downstream targets of mTORc1 (Duran & Hall,
2012). S6k is important for protein synthesis, and 4E-BP1 is particularly important for
controlling cell metabolism and proliferation (Duran & Hall, 2012). So, inhibition of
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mTOR pathway through AMPK activation can lead to inhibition of cell proliferation and
protein synthesis(Dowling et al., 2011). On the other hand, metformin can inhibit mTOR
independent on AMPK activation by affecting REDD1 expression (regulated
development and DNA damage response) and Rag GTPase proteins (Quinn et al., 2013).
Besides, it was shown that metformin treatment can be more toxic to p53 mutant cancer
cells, in which metformin-induced AMPK activation can lead to autophagy or apoptosis
depends on presence or absence of functioning p53. (Buzzai et al., 2007; Quinn et al.,
2013). Thus p53 mutant cancer cells may be more sensitive to energetic stress exerted by
metformin. (Quinn et al., 2013).
Furthermore, a recent clinical trial using metformin therapy in women with breast
cancer, metformin demonstrated inhibitory effect on cancer cell growth evident by
biological markers (Hadad et al., 2011). Likewise, nowadays several preclinical and
clinical trials are being conducted to test the role of metformin, as a promising anticancer
medication, on different cancer types (Ben Sahra et al., 2010; Quinn et al., 2013).

1.3 Published Data:
Despite the great efforts which have been conducted in last years to elucidate the
effect of metformin on various cancer types, not much is known about its effect on
neuroblastoma growth and metastasis. According to previous research published in 2006,
AMPK was activated in SH-SY5Y cell line in response to metformin treatment (GarciaGil et al., 2006). Besides, these cells demonstrated reduction in survival and early
morphological changes suggestive of apoptosis, with significant effect was found 72
hours post metformin treatment (Garcia-Gil et al., 2006).Besides, a published data in
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2013 testing the effect of metformin and other mitochondrial inhibitors (MIBG and
phenformin) on different neuroblastoma cell lines, metformin was able to destabilize
MYC/MYCN, enhance histone H3 acetylation in neuroblastoma cancer cell lines, and
promotes expression of several genes encoded for biomarkers associated with favorable
prognosis (Wang et al., 2014).

1.4 Hypothesis and specific aims:
In our research we propose that metformin, a relatively safe, effective and
inexpensive medication, could be a good candidate for the treatment of pediatric
neuroblastoma. In the current research, we focus mainly on studying the possible in vitro
anticancer effects of metformin on two different human neuroblastoma cell lines, SHSY5Y and the chemo-resistant SKNBE(2). Our research is conducted under following
specific aims:
Specific Aim 1: to test the effect of metformin on neuroblastoma cells growth and
survival.
Specific Aim 2: to determine the effect of metformin treatment on the tumorigenicity of
neuroblastoma cells.
Specific Aim 3: to further investigate possible mechanisms underlie the antineoplastic
effect of metformin on neuroblastoma cells including: AMPK, Akt, and Rho GTPases
signaling pathways.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Cell lines and culture conditions:
Human neuroblastoma cell lines SH-SY5Y and SKNBE (2) were obtained from
the American Type Culture Collection (ATCC; Manassas, VA). Cells were maintained in
Dulbecco’s modified Eagle medium (DMEM ; HyClone Laboratories, South Logan,
Utah) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, GA) and
100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B (AntibioticAntimycotic; Atlanta Biologicals, GA), and allowed to grow at 37˚C in humidified
incubator with 5% CO2. Similar preparation for complete culture medium was used to
grow neuroblastoma cells for all experiments in this research.

2.2 Metformin and Antibodies:
Metformin Hydrochloride (MP Biomedicals; Solon, OH) was dissolved in a
sterile triple distilled water to make 1 Molar stock solution, which is further diluted in
culture media to obtain the desired concentrations (1,10, 20 mM), respectively, for each
experiment. Monoclonal primary antibodies and the compatible secondary antibodies for
western blot analysis and Immunofluorescence assay were obtained from the following
sources: Cleaved Caspase-3 Rabbit Ab, Beta- Actin Rabbit Ab, p-AMPK alpha Rabbit
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Ab, Total AMPK alpha Rabbit Ab, p-Akt Rabbit Ab, and total Akt Mouse Ab (Cell
Signaling Technology, Danvers, MA) Beta- Actin Mouse Ab, goat anti-rabbit IgG-HRP
Ab, goat anti-mouse IgG-HRP Ab, Secondary antibodies conjugated with fluorescein
isothiocyanate (FITC) (Santa Cruz Biotechnology, Dallas, TX)

2.3 Cell proliferation quantification using Trypan blue dye:
Each cell line was cultured in 60 millimeter plates with density of 5×105
cells/plate supplemented with complete culture medium. After 24 hours, the media were
removed, and cells were treated with metformin 1, 10, 20 mM diluted in medium, while
the control received complete medium without metformin. Cells were allowed to grow
under humidified condition for 2, 4, 6 days for SH-SY5Y cells and 2 and 4 days for SKN-BE (2), respectively. At indicated time points, cells were harvested by trypsinization
and centrifuged at 1200 rpm for 5 minutes to get a cell pellet. Cell pellets were suspended
in 1xPBS and live cells (unstained cells) were counted under light microscope using
hemocytometer and trypan blue dye (Sigma-Aldrich).

2.4 MTT colorimetric cell viability assay:
According to manufacture protocol (Roche diagnostics corporation; Indianapolis,
IN), 5×103 cells/well of each cell line were seeded in 96 wells culture plate in triplicate
with complete culture medium. After 24 hours, the medium was removed and cells were
treated with metformin (1, 10, 20 mM), respectively, diluted in 100 µl of complete
culture medium, while the control received medium without metformin. Cells were
treated for 2, 4, 6 days for SH-SY5Y cells and 2 and 4 days for SK-N-BE (2), and at time
of analysis 10 µl/well of MTT (3-4,5-Dimethylthiazol-2-Yl-2,5-Diphenyltetrazolium
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Bromide) labeling reagent was added and incubated at 37 ˚C for 4 hours, followed by
overnight incubation with 100 µl/well of solubilization solution. Cell viability was
measured based on the ability of active viable cells to yield formazan product (purple
color) as a result of cleavage of the yellow Methylthiazol tetrazolium (MTT) salt (Roche
diagnostics corporation). The resulting colored solution was read by spectrophotometer at
550 nm (the absorbance of formazan product which is directly related to the density of
live cells), while the background reference absorbance was read at 690 nm.

2.5 Soft agar colony formation assay:
Approximately

5×104 cells/plate of each cell line were mixed with 0.35%

agarose gel (Amersham) in DMEM medium supplemented with 10% FBS. The
suspension (cells and 0.35% agarose gel) was laid on the top of a solidified bottom layer
of 0.8% agarose gel supplemented with the same culture medium and plated in 35
millimeter cell culture plates. After the top layer was solidified, the two-layer agarose gel
plates (containing cells) were kept at 37ºC in a humidified incubator. After 24 hours, cells
were treated with or without metformin (1, 10, 20 mM) diluted in 500µl /plate complete
DMEM medium. Cells were fed each 4-5 days with DMEM medium containing 10%
FBS with or without (for control) the indicated concentrations of metformin. After 45
days, colonies were stained with 0.1% crystal violet dye and the number of colonies was
counted under the light microscope.

2.6 Immunofluorescence analysis:
Each cells line was grown in Lab-tek II chamber slides (Thermo scientific) in
complete culture medium with 10% FBS. After cells were reached 20-30% confluent,
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they were treated with or without 20mM metformin diluted in medium and kept at 37C in
a humidified incubator. At indicated time points, the growth medium was removed and
cells were washed with 1x PBS and fixed with 4% paraformaldehyde in PBS for
approximately 20 minutes. Cells then were permeabilized with 0.1% Triton X-100 in
PBS for 10 minutes and washed again with 1x PBS. Cells were incubated with blocking
reagent of 10% immunoglobulin free-bovine serum albumin ( Jackson Immune Research
Laboratories, PA) in 1 x PBS for overnight at 4˚C. Cells were incubated for overnight
with cleaved caspase-3 primary antibody in 2.5% IgG-free BSA/PBS at 4˚C. FITC (Santa
Cruz Biotechnology, TX) secondary antibody in 2.5% IgG-free BSA/PBS was used to
detect cleaved caspase-3 after 2 hours incubation at room temperature. Slides then
washed with 1 x PBS followed by adding of antifade Vectashield mounting media
(Vector Laboratories, CA), and the nucleus was counterstained with DAPI (4',6diamidino-2-phenylindole;Sigma). Signals for cleaved caspase3 and nucleus were
visualized under fluorescence microscope (Nikon-E600, Tokyo, Japan).

2.7 Western blots analysis:
Cells were plated in 100 millimeter plates with DMEM culture medium supplemented
with 10% FBS. After they reached 20-30% confluent, cells were treated with metformin
(1, 10, 20 mM) diluted in 10 ml complete culture medium for 4 and 6 days for SK-N-BE
(2) and SH-SY5Y cells, respectively, while the control received culture medium without
metformin. At indicated time points, cells were harvested and lysed in RIPA lysis buffer
and protein concentration was estimated using bicinchoninic acid protein assay (BCA
assay; Thermo scientific, Rockford, IL). Equal amount of protein samples were denatured
by heating with Laemmli loading dye containing 2-Mercaptoethanol(Bio-Rad
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laboratories; Hercules, CA). Protein samples were resolved by electrophoresis using 1014% Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis or SDS-PAGE (30%
acrylamide/Bis solution, 1.5M Tris-Hcl buffer pH 8.8(Bio-RAD laboratories), 10%
sodium dodecyl sulfate SDS (Biomedicals Inc), 10% Ammonium per Sulfate,
Tetramethylethylenediamine or TEMED (Fisher BioReagents)). Proteins were transferred
to polyvinyl difluoride (PVDF; Amersham, Buckinghamshire, NA) membrane and then
blocked with 5% non-fat dry milk for 2 hours at room temperature or 10% Bovine serum
Albumin or BSA for overnight at 4˚C.Western blots membranes were incubated with
either monoclonal primary antibodies diluted in 2.5% nonfat dry milk/TBST (1:1000
dilution) or 5% BSA/TBST (1:1000 dilution) for overnight at 4 ˚C.
After washing with 1xTBST, a compatible secondary antibody was added
(1:2000-4000 dilution in milk or BSA/TBST) and incubated for 1-2 hours at room
temperature

followed

by

wash

with

1xTBST.

ECL

substrate

(Enhanced

Chemiluminescence; Bio-Rad laboratories) were used to reveal protein of interest and the
signal was detected using radiographic film (Thermo Scientific).

2.8 Statistical analysis:
Statistical analysis was performed using GraphPad InStat software (GraphPad
Software, Inc. La Jolla, CA). For data from 3 experiments, the average results were
calculated and the error bar represents the standard deviation of the mean. One-way
ANOVA was performed followed by Tukey-Kramer test to compare significance among
treated group relative to control (p-value < 0.05 was considered significant).

26

CHAPTER 3
RESULTS
3.1Metformin exerts growth
neuroblastoma cell lines:

and

survival

inhibitory

effects

on

To test the growth inhibitory effect of metformin on SH-SY5Y cell line and the
chemo-resistant SK-N-BE2 cell line, cells were grown in complete culture media
supplemented with 10% FBS in presence or absence of metformin (1,10,20 mM) for 6
and 4 days, respectively. The results of viable cells count using trypan blue dye
demonstrate that metformin significantly inhibit cell proliferation at concentrations of (10
and 20 mM) in time and dose dependent pattern relative to control, in both cell lines,
while no significant effect were found at the lower concentration (1 mM) (Figure3.1
A&B). Besides, the morphological changes of treated cells were examined daily under
light microscope and compared to the control. We noticed morphological changes
suggestive of apoptosis at (10 mM and 20mM) metformin treated groups, which started at
day 2 in SK-N-BE2 cells and at day 4 in SH-SY5Y cells, while more drastic changes
were noticed at day 4 for SK-N-BE2 and day 6 for SH-SY5Y cells, when marked number
of cells became rounded and started lifting, (Figure 3.1 C), as reported in our previous
work (Kumar, Al-Sammarraie, DiPette, & Singh, 2014). To further confirm our results,
MTT colorimetric assay was performed to check the enzymatic activity of both cell lines,
which directly correlated with cell viability (Roche diagnostics corporation; Indianapolis,
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IN). Our results show that metformin was significantly able to inhibit cells viability at
(10 and 20 mM) in time and dose dependent manner for both N-MYC amplified and non
N-MYC amplified cells. However, no significant effect on cell viability was noticed at (1
mM) treated group compared to the control (Figure 3.2 A&B).

3.2 Metformin inhibits the anchorage-independent colony formation of both
neuroblastoma cell lines:
In order to test the ability of metformin to inhibit anchorage-independent
malignant growth of neuroblastoma cells in vitro, we monitored colony formation of SHSY5Y and SK-N-BE2 cells seeded on a two-layered agarose gel and treated with
metformin at different concentrations (1, 10, 20 mM) ,versus the untreated control group,
over 45 days. Cells were fed every 4-5 days with fresh complete medium containing the
indicated concentrations of metformin, while control group received culture media
without metformin. At indicated time point, the number of established colonies was
counted under the light microscope, and the number of colonies in treated groups was
compared relative to the control. Our preliminary data suggest that metformin was able to
inhibit colony formation of neuroblastoma cells at (10 and 20 mM) respectively in both
cell lines (figure 3.3A&B). However, no significant effect on colony formation was
found at the lower concentration (1mM) treated group.

3.3 Metformin induces apoptosis in neuroblastoma cell lines:
In order to check the anti-survival effect of metformin on neuroblastoma cell
lines, SK-N-BE (2) and SH-SY5Y cells were grown in presence or absence of 20 mM
metformin for 4 and 6 days, respectively. At the indicated time points,
immunofluorescent staining was performed using anti-cleaved caspase3 antibody, which
28

detect the active form of caspase3. Our results show that metformin was able to induce
apoptosis through activation of caspase 3 in both cell lines reflected by the green
cytoplasmic signal of the cleaved active form, especially when counter staining of the
nucleus with DAPI was performed (Figure 3.4 A). Besides, western blot analysis was
performed to detect cleaved caspase 3 band using whole cell lysates of SK-N-BE(2) and
SH-SY5Y cells treated with 1,5,10, or 20 mM metformin, for 4 and 6 days respectively,
compared to untreated control. Our results demonstrate that metformin induced marked
activation of caspase 3 in both cell lines at (10 and 20 mM) revealed by western blot
bands, while no difference was found at 1mM relative to control, (Figure 3.4.B), as
indicated in our previous work (Kumar et al., 2014).

3.4Metformin’s anti-proliferative and anti-survival effects may be
independent on AMPK and AKT pathways:
To further check the possible pathways by which metformin could exert its
antineoplastic effects, SK-N-BE (2) and SH-SY5Y were treated with(1, 10, 20 mM)
metformin for 4 and 6 days, respectively, and the level AMPK phosphorylation was
measured using western blot analysis of pAMPK (phosphorylated AMPK). We observed
slight increase in the level of pAMPK in the treated group of both cell lines relative to
control. We further measured the total AMPK to get the ratio of pAMK/total AMPK. Our
results show that the level of phosphorylation of AMPK in both cell lines was statistically
insignificant relative to the control, (Figure 3.5 A&B), as reported in our previous work
(Kumar et al., 2014). Similarly, we checked the effect of metformin on Akt survival
pathway, in which Akt activation is frequently associated with high stage neuroblastoma
(Santo et al., 2013). Our preliminary data suggest that metformin treatment has no
marked effects on pAkt or total Akt proteins expression, demonstrated by western blot
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analyses of whole cell lysates of treated cells relative to control, (Figure 3.6), similar to
previous work (Kumar et al., 2014).

3.5 Metformin effect on Rho GTPases protein expression:
Rho GTPases are small G-proteins belong to Ras superfamily and play vital role
in cell growth and proliferation (Shang et al., 2012). Metformin anticancer effect noticed
in many cancer types works mainly through inhibition of mTOR/S6k pathway, and S6k is
regulated by Rho GTPases (Chou & Blenis, 1996; Dowling et al., 2011). In this study, we
performed western blot analysis using whole cell lysates of SK-N-BE (2) and SH-SY5Y
cells to detect a change in total RhoA and Rac1 small GTPases proteins expression post
metformin (1,10, 20 mM) treatment, for 4 and 6 days, respectively. Our initial data
suggest that metformin markedly reduced total RhoA expression in both cell lines at 10
and 20mM concentrations relative to control (Figure3.7A). Similarly, total Rac1
expression was reduced in response to metformin (10 mM and 20 mM) treatment in SKN-BE(2), while no marked change was detected in SH-SY5Y total Rac1 protein
expression compared to control (Figure3.7B).
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Figure 3.1 The effect of metformin on neuroblastoma cells proliferation (A) Live cells
count of SH-SY5Y cells treated with metformin (1, 10, 20 mM) for 6 days duration, N=3,
error bars represent ± SD of the mean. (B)Live cells count of SK-N-BE2 cells treated
with metformin (1, 10, 20 mM) for 4 days duration, N=3, error bars represent ± SD of the
mean. (C) Representative images of morphological changes accompanied metformin
treatment on both cell lines.
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Figure 3.2 The effects of metformin on neuroblastoma cell viability (A) Cell viability
estimated by MTT assay of SH-SY5Y cells treated with metformin (1, 10, 20 mM) for 6
days duration, N=3, and error bars represent the ± SD of the mean. (B) Cell viability
estimated by MTT assay of SK-N-BE (2) cells treated with metformin (1, 10, 20 mM) for
4 days duration, N=3, and error bars represent the ± SD of the mean.
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Figure 3.3 The effects of metformin on neuroblastoma colony formation. (A) Number of
colonies of SH-SY5Y cells treated with metformin for 45 days and expressed as fold
change relative to control, N=triplicate, and error bar represent ±SD of the mean. (B)
Number of colonies of SK-N-BE(2) cells treated with metformin for 45 days and
expressed as fold change relative to control, N=triplicate, and error bar represent ±SD of
the mean.
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Figure3.4 Metformin induces apoptosis of neuroblastoma cell lines (A)
Immunofluorescence staining for cleaved caspase 3 detection in SH-SY5Y and SK-NBE(2) treated with 20mM metformin for 6 and 4 days respectively. (B) Western blot
analysis for cleaved caspase 3 in SH-SY5Y and SK-N-BE(2) cells treated with 1,5,10, or
20 mM metformin for 6 and 4 days respectively, relative to control N=3.
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Figure 3.5 The effect of metformin on AMPK activation in neuroblastoma cells: (A)
Western blot analysis of AMPK (phosphorylated and total protein) in SH-SY5Y and SKN-BE (2) treated with 1, 10, or 20mM metformin for 6 and 4 days, respectively, relative
to control (B) Corresponding signal density of the ratio of pAMPK /Total AMPK
measured by Image J software, N=3, and error bars represent ±SD of the mean.
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Figure 3.6 The effect of metformin on AKT activation in neuroblastoma cells. Western
blot analysis of AKT (phosphorylated and total protein) in SH-SY5Y and SK-N-BE (2)
treated with 1, 10,or 20mM metformin for 6 and 4 days, respectively, relative to control,
N=1-2.
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Figure 3.7 The effect of metformin on Rho GTPases protein expression in neuroblastoma
cells: (A) Western blot analysis of RhoA total protein expression in SH-SY5Y and SK-NBE (2) treated with (1, 10,or 20mM) metformin for 6 and 4 days, respectively, relative to
control, N=1-2. (B) Western blot analysis of Rac1 total protein expression in SH-SY5Y
and SK-N-BE (2) treated with (1, 10, 20mM) metformin for 6 and 4 days, respectively,
relative to control, N=1-2.
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CHAPTER 4
DISCUSSION
Neuroblastoma is a heterogeneous tumor with combination of several molecular
and genetic abnormalities (Davidoff, 2012).These genetic aberrations can develop both in
primary tumor and after chemotherapy which make the tumor difficult and sometime
unresponsive to the treatment (Tweddle et al., 2001; Van Roy et al., 2009). Despite the
combination of different modalities for treatment of neuroblastoma, still the survival rate
low for high-risk group (American Cancer Society, 2014). Besides, the current treatment
for high risk neuroblastoma may depend on intensified chemotherapy, which itself can
carry serious complications for patients(American Cancer Society, 2014). In recent years,
several laboratory studies have been performed testing the effect of metformin on
different cancer types, which demonstrate marked anti-cancer effect of metformin on
different cancers both in vitro and in vivo (Quinn et al., 2013). Moreover, metformin is
worldwide approved first line medication for treatment of type 2 diabetes, due to the fact
that it is relatively safe with mild side effects and rare complication of lactic acidosis
(Ben Sahra et al., 2010; Rojas & Gomes, 2013). Besides, in recent years, clinical trials
using metformin treatment in children and adolescence with type 2 diabetes have been
conducted and showed that metformin treatment reduce blood glucose level (fasting) and
body weight, without evidence of severe side effects, such as hypoglycemia or lactic
acidosis(Rojas & Gomes, 2013). So, recently great work have been performed
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studying the effect of metformin therapy on various cancer types, however, there is not
much known about the effect of metformin on neuroblastoma.
In this study, in vitro experiments were performed to test the effect of metformin
on neuroblastoma cell lines, as metformin relatively safe drug with remarkable in vivo
and in vitro anticancer effects and, in some cancer types, works more effectively on p53
deficient cancer cells (Ben Sahra et al., 2010; Quinn et al., 2013). In this research,
metformin anticancer effect on neuroblastoma cells was conducted using two different
cell lines to mimic the heterogenic nature of neuroblastoma : SH-SY5Y, a subline of SKN-SH cells derived from bone marrow aspirate of neuroblastoma lesions, which is Nmyc non-amplified (Xie, Hu, & Li, 2010; Wang et al., 2014), and SK-N-BE(2), a cell line
derived from bone marrow biopsy of relapsed neuroblastoma lesions, which is N-myc
amplified and p53 mutant (loss of function mutation) (Tweddle et al., 2001; Wang et al.,
2014). We first tested the effect of metformin on cell proliferation and survival using low
and high concentrations of metformin (1-20 mM), which is similar to in vitro
concentrations used in other studies (Ben Sahra et al., 2010). Our results suggest that
metformin at 10 and 20 mM was markedly able to inhibit growth and survival of both
neuroblastoma cell lines, similar to our previous work (Kumar et al., 2014) and to many
in vitro studies testing the effect of metformin on different cancer types, such as breast
cancer and pancreatic carcinoma (Ben Sahra et al., 2010).
In addition, we observed morphological changes in cells being smaller and
rounded which were more marked at day 4 and 6 for SK-N-BE (2) and SH-Y5Y,
respectively, as reported previously (Kumar et al., 2014). Our finding is similar to
previous study when metformin was able induce morphological changes suggestive of
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apoptosis in SH-SY5Ycells with more significant effect noticed after 72 hours from
treatment (Garcia-Gil et al., 2006). Besides, in some in vitro studies, metformin was able
to induce apoptosis such as in triple negative breast cancer with caspases activation (B.
Liu et al., 2009). So, we performed immunofluorescence staining to checked the
expression of cleaved caspase-3 protein, an apoptotic marker indicative of the active
effector caspase-3 (Fan & Bergmann, 2010), in 20 mM metformin treated SK-N-BE (2)
and SH-SY5Y cells for 4 and 6 days, respectively, versus the control. Our results suggest
that caspase-3 was activated in treated group which revealed by presence of green
immunofluorescence cytoplasmic signals. We further confirmed our results by detecting
cleaved caspase-3 band, using western blot analysis, and it was found to be markedly
activated in 10 and 20 mM treated cells at same time points, as indicated in our previous
work (Kumar et al., 2014).
The next part of our study focused on understanding the molecular pathways by
which metformin may work as anticancer medication. We used western blot analysis of
whole cell lysates of SK-N-BE (2) and SH-SY5Y treated with metformin for 4 and 6
days respectively, to check different possible pathways by which metformin could inhibit
growth and/or survival of neuroblastoma cells, including: AMPK activation, AKT
inhibition, and change in Rho GTPases protein expressions. These preliminary data could
be helpful as a start point for our ongoing and future work exploring the anticancer effect
of metformin on neuroblastoma.
In many studies, metformin has been found to work through AMPK dependent
pathway to inhibit cell growth of different cancer cell types (Dowling et al., 2011; Viollet
et al., 2012). In previous study using SH-SY5Y neuroblastoma cell line, AMPK was
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activated in these cells 3 hours post metformin treatment (Garcia-Gil et al., 2006). Our
results demonstrate that AMPK phosphorylation in metformin treated cell lines for longer
time periods was statistically insignificant compare to control (Kumar et al., 2014).
However, further study is needed to test whether metformin inhibit AMPK acutely at
early time points that might lead to inhibition of cell growth and survival.
On the other hand, several studies have shown that metformin may work through
targeting AKT pathway, via AMPK dependent or independent mechanism. Xiaona Liu et
al reported that metformin inhibits cell growth of Glioblastoma cells by promoting
PRAS40 (AKT substrate) association with RAPTOR, which ultimately inhibited mTOR
independent on AMPK activation (X. Liu et al., 2014). Besides, in vivo study testing the
effect of metformin on prevention of tobacco induced lung cancer; metformin was able to
inhibit AKT activation and other pathways in lung tissue independent on AMPK, leading
to attenuation of lung tumorgenesis. (Memmott et al., 2010). However, Zakikhani et al
show that metformin was able to induce apoptosis in breast cancer cells due to the effect
of metformin on inhibition of AKT pathway, beside mTOR inhibition, through AMPK
dependent mechanism (Zakikhani, Blouin, Piura, & Pollak, 2010).

AKT is a

serine/threonine kinase which plays important role in regulation of cell growth and
survival(Megison, Gillory, & Beierle, 2013). Akt activation has been found to be
associated with high stage neuroblastoma, and found to be important for MYCN posttranslation stabilization; hence, it is important for cancer cell growth and proliferation
(Santo et al., 2013). So, to test if metformin can inhibit AKT pathway in neuroblastoma
cells, we checked pAkt expression using western blot analysis to see whether metformin
treatment can inhibit this survival pathway to arrest growth and induce apoptosis. Our
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preliminary data suggest that metformin works in an Akt-independent mechanism, as no
marked change was noticed on pAKT protein expression in treated groups of both cell
lines compared to control, similar to previous work (Kumar et al., 2014).
Similarly, we tested the effect of metformin on Rho GTPases proteins expression,
as they are pivotal signaling molecules involved in cell growth, cell cycle progress and
metastasis. (Shang et al., 2012). Metformin is known to affect S6 kinase pathway, and
this pathway is regulated by Rho GTPases (Chou & Blenis, 1996; Dowling et al., 2011).
So, we tested whether metformin could be targeting Rho GTPases signaling to inhibit
growth and survival of neuroblastoma cells. RhoA and Rac1 are small GTPases proteins
belong to Ras superfamily and they are well regulated in the cell in response to different
cell conditions (Shang et al., 2012). Upon activation, with aid of Rho guanine nucleotide
exchange factors (GEFs), they switch from GDP-bound inactive state to GTP-bound
active state (Shang et al., 2012). Rho GTPases activities, especially RhoA, have been
found to be upregulated in various cancer types and associated with cancer metastasis and
growth; hence, targeting this vital pathway that control cell growth has been conducted in
recent research (Shang et al., 2012). Rac1 is a small GTPase protein which controls
S6kinase activity that plays role in cell passage from G1 to S phase through cell cycle
(Chou & Blenis, 1996). It is also important for regulation of cell migration and
cytoskeleton organization(Dirat et al, 2014). In recent study testing the effect of
metformin on metastasis of prostatic cancer cells in nude mice, metformin was able to
inhibit Rac1 GTPases activity by affecting several upstream signaling pathways, which in
turn reduced cancer cells migration and metastasis (Dirat et al, 2014). In our studies we
checked whether metformin affect expression of Rac1 using western blot analysis. Our
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preliminary data suggest that metformin was able to inhibit total Rac1 protien expression
in SK-N-BE (2) cells, while no marked difference is found on Rac1protien expression in
SH-SY5Y cells compare to control. Likewise, we checked the effect of metformin on
Rho/ROCK pathway, which is important for cell proliferation, migration, differentiation,
malignant transformation and apoptosis (Ohta et al., 2012). In a published data regarding
human ovarian cancer cells, inhibition of Rho/ROCK pathway, using fasudil inhibitor,
promoted the anticancer effect of cisplatin in these cell lines (Ohta et al., 2012).
Similarly, we tested the effect of metformin on this vital pathway using western blot
analysis to check the total RhoA protein expression in treated cells. Our results
demonstrated that metformin reduces the total RhoA protein expression in both cell lines,
which may play a role in its anticancer effects. However, further in vitro studies are
important to test the effect of metformin on Rho GTPases activity by measuring the
relative ratio of active protein form to the total expression. In conclusion, our results
imply that metformin, a relatively safe drug with wide clinical applications, could be a
promising anticancer candidate for treatment of neuroblastoma in the future.
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